Brief: First Wave Biopharma Announces Streamlining Of Clinical Pipeline With Non-Binding Term Sheet To Sell Niclosamide Ibd Program

GridAI Technologies

27/12/2023 11:03

Dec 27 (Reuters) - First Wave BioPharma Inc  FWBI.O :
    * FIRST WAVE BIOPHARMA ANNOUNCES STREAMLINING OF CLINICAL
PIPELINE
WITH NON-BINDING TERM SHEET TO SELL NICLOSAMIDE IBD PROGRAM
    * NON-BINDING TERM SHEET INCLUDES A LOW SEVEN-FIGURE UPFRONT
PAYMENT TO FIRST WAVE BIOPHARMA FOR RIGHTS TO NICLOSAMIDE
    * ENTERED A NON-BINDING TERM SHEET TO SELL ITS NICLOSAMIDE
PROGRAM
FOR TREATMENT OF INFLAMMATORY BOWEL DISEASES
    * PROPOSED DEAL WILL ENABLE FIRST WAVE BIOPHARMA TO FOCUS
ITS
DEVELOPMENT RESOURCES ON ITS THREE LATE-STAGE CLINICAL PROGRAMS
    * RECENTLY REINVIGORATED OUR GI-FOCUSED CLINICAL DEVELOPMENT
PIPELINE

Source text for Eikon:  ID:nGNX7zMWJ7 
Further company coverage:  FWBI.O 

 ((Reuters.Briefs@thomsonreuters.com;))